Systematic review and meta-analysis of the prognostic significance of microRNAs in cervical cancer

Zhilan Chen; Yingyan Han; Chengwen Song; Huafang Wei; Ying Chen; Kecheng Huang; Shuang Li; Ding Ma; Shixuan Wang; Jing Wang; Qiping Lu

doi:10.18632/oncotarget.23839

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Systematic review and meta-analysis of the prognostic significance of microRNAs in cervical cancer

Zhilan Chen _, Yingyan Han, Chengwen Song, Huafang Wei, Ying Chen, Kecheng Huang, Shuang Li, Ding Ma, Shixuan Wang, Jing Wang and Qiping Lu

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:17141-17148. https://doi.org/10.18632/oncotarget.23839

Metrics: PDF 1530 views | HTML 1936 views | ?

Abstract

Zhilan Chen1,*, Yingyan Han2,*, Chengwen Song1, Huafang Wei1, Ying Chen1, Kecheng Huang2, Shuang Li2, Ding Ma2, Shixuan Wang2, Jing Wang1 and Qiping Lu3

1Department of Obstetrics and Gynecology, Wuhan General Hospital of People’s Liberation Army of China, Wuhan, Hubei, China

2Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

3Department of General Surgery, Wuhan General Hospital of People’s Liberation Army of China, Wuhan, Hubei, China

*These authors contributed equally to this work

Correspondence to:

Jing Wang, email: [email protected]

Qiping Lu, email: [email protected]

Keywords: cervical cancer; miRNA; prognosis; meta-analysis

Received: February 03, 2017 Accepted: October 05, 2017 Epub: December 16, 2017 Published: March 30, 2018

ABSTRACT

In this meta-analysis, we analyzed case-control studies that assessed the prognostic potential of miRNAs in cervical cancer. We comprehensively searched EMBASE and PubMed databases and enrolled seven studies with 445 cervical cancer cases. A fixed effects model was used to calculate pooled hazard ratios (HRs) and associated 95% confidence intervals (95% CIs) from the overall survival (OS) data. Our analysis showed that poor OS in cervical cancer was associated with low miR-125 expression (HR = 1.61, 95% CI: 1.02–2.55, P = 0.042; I² = 10.1%, P = 0.292; n = 99), low miR-145 expression (HR = 1.70, 95% CI: 1.29–2.24, P < 0.001; I² = 0%, P = 0.560; n = 193) and high miR-196 expression (HR = 0.28, 95% CI: 0.15–0.52, P < 0.001; I² = 0%, P = 0.950, n = 197). This makes microRNAs such as miR-125, miR-145 and miR-196 potential prognostic biomarkers in cervical cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23839

Publication Alerts

Meta-Analysis:

Systematic review and meta-analysis of the prognostic significance of microRNAs in cervical cancer

Abstract